This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
Consensus papers

EAS Consensus Position Paper Initiative

Since 2009, the European Atherosclerosis Society has brought together internationally renowned experts in specific key aspects of atherosclerosis and cardiovascular disease, to publish a series of consensus publications addressing topical issues of major relevance to our membership and the scientific community. The Consensus Panel is co-chaired by Professors John Chapman, Henry Ginsberg and Alberico L. Catapano. The Papers have been published in high-impact journals and are widely cited.

Publications by the Consensus Panel

Listed in order of publication year, more recent, first.

Low-density lipoproteins cause atherosclerotic cardiovascular disease; pathophysiological, genetic and therapeutic insights. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Rare Dyslipidaemias: From Phenotype to Genotype to Management. A European Atherosclerosis Society Task Force Consensus Statement.
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.
2017 Update of ESC/EAS Task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. 
ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors.
Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. 
Familial Hypercholesterolaemia in children and adolescents: gaining decades of life by optimising detection and treatment. Consensus Statement of the European Atherosclerosis Society.
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Consensus Statement of the European Atherosclerosis Society.
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Consensus Statement of the European Atherosclerosis Society. 
Consensus Position Paper on plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Consensus Statement of the European Atherosclerosis Society. 
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Consensus Statement of the European Atherosclerosis Society.
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. 
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Consensus Statement of the European Atherosclerosis Society.
Lipoprotein(a) as a cardiovascular risk factor: current status. Consensus Statement of the European Atherosclerosis Society.
Membership Software Powered by YourMembership  ::  Legal